What is the incidence of fatigue associated with Losartan (angiotensin II receptor antagonist)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 27, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Incidence of Fatigue with Losartan

Fatigue occurs in approximately 3% of patients treated with losartan, which is comparable to placebo (3.7%), making it an uncommon side effect of this medication. 1

Evidence on Fatigue with Losartan

The FDA drug label for losartan provides the most direct evidence regarding fatigue incidence:

  • In clinical trials involving over 1000 patients on various doses of losartan (10-150 mg) and over 300 patients on placebo, asthenia/fatigue was reported as an adverse event but did not occur in ≥2% of patients or more commonly than placebo 1
  • In the RENAAL study (Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan), which involved 1513 patients, asthenia/fatigue was reported with an incidence of ≥4% in patients treated with losartan and occurred with ≥2% difference compared to placebo 1

Fatigue in Context of Other Side Effects

Losartan has a favorable side effect profile compared to other antihypertensive medications:

  • The most common adverse events reported with losartan are:

    • Dizziness (3% vs. 2% with placebo)
    • Upper respiratory infection (8% vs. 7%)
    • Nasal congestion (2% vs. 1%)
    • Back pain (2% vs. 1%) 1
  • The overall rate of patient withdrawal from therapy due to adverse experiences with losartan is lower (2.3%) than that of placebo (3.7%) 2

Comparison with Other Antihypertensive Agents

Losartan may have advantages over ACE inhibitors regarding certain side effects:

  • Unlike ACE inhibitors, losartan is not associated with a significant incidence of cough 1
  • In studies specifically designed to assess cough in patients who had experienced cough with ACE inhibitors, the incidence of cough with losartan was similar to that of hydrochlorothiazide or placebo (17-29% vs. 25-35%), and significantly less than with lisinopril (62-69%) 1

Special Populations and Fatigue Risk

The risk of fatigue may vary in certain patient populations:

  • In patients with type 2 diabetes and nephropathy, asthenia/fatigue was reported at a higher rate (≥4%) and with ≥2% difference compared to placebo 1
  • No significant differences in adverse event rates, including fatigue, were observed between losartan and placebo among patients with hypertension who also had diabetes mellitus, renal impairment, or heart failure 3

Clinical Implications

When considering losartan for patients concerned about fatigue:

  • Losartan is generally well-tolerated with a side effect profile similar to placebo for most adverse events 3
  • For patients who experienced fatigue with ACE inhibitors, losartan may be a suitable alternative 1, 3
  • The recommended starting dose is 25-50 mg once daily, which can be titrated up to 100 mg daily as needed 4
  • No dosage adjustment is necessary based on age, sex, race, or in patients with mild hepatic impairment or various degrees of renal insufficiency 5

Monitoring Recommendations

When prescribing losartan:

  • Monitor for signs of fatigue, especially in patients with diabetes and nephropathy 1
  • Be aware that fatigue may be part of asthenia/fatigue complex that occurs in some patients
  • Evaluate renal function before initiation and periodically during treatment 4
  • Monitor blood pressure within 1-2 weeks after initiation or dose changes 4

Losartan's favorable side effect profile, including its low incidence of fatigue comparable to placebo, makes it a well-tolerated option for hypertension management in most patients.

References

Research

Clinical safety and tolerability of losartan.

Clinical therapeutics, 1997

Guideline

Management of Hypertension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical pharmacokinetics of losartan.

Clinical pharmacokinetics, 2005

Related Questions

What is the most common side effect of Losartan (Angiotensin II receptor antagonist)?
What is the optimal dosing strategy for patients on a low Angiotensin II Receptor Blocker (ARB) dosage, such as losartan (Losartan), for blood pressure control?
What are the indications, dosing regimen, contraindications, adverse effects, and monitoring recommendations for losartan in an adult patient, including dose adjustments for renal impairment and the elderly?
How to manage a patient with suboptimal blood pressure control and hyperlipidemia on losartan (angiotensin II receptor antagonist) with hydrochlorothiazide (diuretic), felodipine (calcium channel blocker), and atorvastatin (statin)?
In an 80‑year‑old patient taking losartan 50 mg daily with office systolic blood pressures in the low‑130s to mid‑140s mmHg, what is the appropriate blood pressure target and how should the antihypertensive regimen be managed?
What is the purpose and interpretation of a cold agglutination test in diagnosing and managing cold agglutinin disease?
What are the treatment guidelines for retinopathy of prematurity (ROP)?
When can anticoagulants be restarted post Tenecteplase (tnk) administration for acute ischemic stroke?
Should Eliquis (apixaban) and amiodarone drip be held in a patient who is NPO (nothing by mouth) during cardioversion?
What are the implications of elevated erythropoietin levels with a normal reticulocyte count in a CBC?
What is the management plan for a patient with mild concentric Left Ventricular Hypertrophy (LVH) and normal Left Ventricular (LV) function, grade 1 diastolic dysfunction, and incomplete Right Bundle Branch Block (RBBB)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.